tiprankstipranks
HUTCHMED to Present Promising Clinical Data in 2024
Company Announcements

HUTCHMED to Present Promising Clinical Data in 2024

HUTCHMED (China) Limited (HK:0013) has released an update.

Don't Miss our Black Friday Offers:

HUTCHMED (China) Limited is set to showcase new clinical data at the 2024 ASH Annual Meeting and ESMO Asia Congress, highlighting the efficacy of its drug sovleplenib in treating chronic primary immune thrombocytopenia in China. The data reveals promising long-term results, with a significant percentage of patients showing sustained improvement in platelet counts. This development underscores HUTCHMED’s commitment to advancing cancer and immunological therapies.

For further insights into HK:0013 stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks UK Auto-Generated NewsdeskHUTCHMED Appoints Experienced Director to Board
TheFlyHutchmed announces new, updated data from sovleplenib ESLIM-01 trial
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App